Caterina Lucano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Caterina Lucano has a total of 236 co-authors. Here are the top co-authors by number of shared publications:
- Ana Rath
Inserm, US14-Orphanet, Paris, France
7 shared publications - David Lagorce
US14-Orphanet, Inserm, Paris, Île-de-France, France
5 shared publications - Marc Hanauer
US14-Orphanet, Inserm, Paris, Île-de-France, France
4 shared publications - Annie Olry
US14-Orphanet, Inserm, Paris, Île-de-France, France
2 shared publications - Aysegul Dilsizoglu Senol
US14-Orphanet, Inserm, Paris, Île-de-France, France
2 shared publications - Charlotte Rodwell
US14-Orphanet, Inserm, Paris, Île-de-France, France
2 shared publications
Latest Publications
- Open Access
- 8 July 2026
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 14, e84553
The Orphanet Nomenclature and Classification of Rare Diseases for Improved Patient Recognition and Data Interoperability: Qualitative and Quantitative Analysis.
Although individually uncommon, rare diseases (RDs) collectively affect an estimated 329-624 million people worldwide. There are over 6500 known RDs, 85% of which affect fewer than 1 person per million. Consequently, the critical amount of data necessary to improve knowledge, care, and treatment can only be achieved through cumulative data collection across countries. However, RDs remain underrepresented in medical terminologies and classification systems, hindering data sharing, interoperability, and public health monitoring. This paper presents the Orphanet Nomenclature and Classification of RDs detailing its content, production and update methodology, and mappings to other semantic resources. It also provides an up-to-date count of RDs based on the consensus operational definition describing their distribution by medical domain. The Orphanet Nomenclature of RDs is a multilingual standardized system composed of clinical entities, each defined by a unique and time-stable ORPHAcode, a preferred term, synonyms, a classification level, and a textual definition. This nomenclature is structured into 3 classification levels organized within a multihierarchical and multiparental classification system by medical domain. Its production, updates, and mappings to major biomedical resources rely on standardized and published procedures, continuous literature review, manual curation, and expert validation, reflecting advancements in RDs knowledge and clinical practice. Presented data metrics were computed using the Orphanet July 2025 release to quantitatively characterize the content, structure, classification, and semantic alignments of the Orphanet Nomenclature and Classification system. As of July 2025, the Orphanet Nomenclature of RDs includes a total of 9784 active clinical entities, including 6527 disorders (corresponding to the RDs definition), 1084 subtypes of disorders, and 2173 groups of disorders. Disorders are multiclassified into 29 classification hierarchies, each corresponding to a distinct medical domain, accurately representing the complex multisystemic nature of RDs. Extensive qualified mappings ensure semantic interoperability: 97.4% (6355/6527) of disorders are mapped to at least 1 ICD-10 (International Statistical Classification of Diseases, Tenth Revision) code (415/6527, 6.4% with an exact proximity relationship), 71.8% (4683/6527) are mapped to at least 1 ICD-11 (International Classification of Diseases, Eleventh Revision) Mortality and Morbidity Statistics code (958/6527, 14.7% with an exact relationship) and 94.8% (6191/6527) are mapped to Systematized Nomenclature of Medicine Clinical Terms (all with an exact relationship). Genetic disorders represent 72.2% (4715/6527) of all RDs, and 63.4% (4141/6527) are mapped to at least 1 phenotypic Online Mendelian Inheritance in Man number. The Orphanet Nomenclature and Classification of RDs is the only RDs-specific interoperable medical terminology meeting the needs of health care, research, and public health systems. By addressing the underrepresentation of RDs in medical terminologies, it enables accurate RDs identification, coding, and monitoring, supporting cross-border data interoperability, and contributing to improved knowledge, policymaking, and ultimately better care for people living with an RD.
- 8 July 2026
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 14, e84553
Open AccessThe Orphanet Nomenclature and Classification of Rare Diseases for Improved Patient Recognition and Data Interoperability: Qualitative and Quantitative Analysis.
Although individually uncommon, rare diseases (RDs) collectively affect an estimated 329-624 million people worldwide. There are over 6500 known RDs, 85% of which affect fewer than 1 person per million. Consequently, the critical amount of data necessary to improve knowledge, care, and treatment can only be achieved through cumulative data collection across countries. However, RDs remain underrepresented in medical terminologies and classification systems, hindering data sharing, interoperability, and public health monitoring. This paper presents the Orphanet Nomenclature and Classification of RDs detailing its content, production and update methodology, and mappings to other semantic resources. It also provides an up-to-date count of RDs based on the consensus operational definition describing their distribution by medical domain. The Orphanet Nomenclature of RDs is a multilingual standardized system composed of clinical entities, each defined by a unique and time-stable ORPHAcode, a preferred term, synonyms, a classification level, and a textual definition. This nomenclature is structured into 3 classification levels organized within a multihierarchical and multiparental classification system by medical domain. Its production, updates, and mappings to major biomedical resources rely on standardized and published procedures, continuous literature review, manual curation, and expert validation, reflecting advancements in RDs knowledge and clinical practice. Presented data metrics were computed using the Orphanet July 2025 release to quantitatively characterize the content, structure, classification, and semantic alignments of the Orphanet Nomenclature and Classification system. As of July 2025, the Orphanet Nomenclature of RDs includes a total of 9784 active clinical entities, including 6527 disorders (corresponding to the RDs definition), 1084 subtypes of disorders, and 2173 groups of disorders. Disorders are multiclassified into 29 classification hierarchies, each corresponding to a distinct medical domain, accurately representing the complex multisystemic nature of RDs. Extensive qualified mappings ensure semantic interoperability: 97.4% (6355/6527) of disorders are mapped to at least 1 ICD-10 (International Statistical Classification of Diseases, Tenth Revision) code (415/6527, 6.4% with an exact proximity relationship), 71.8% (4683/6527) are mapped to at least 1 ICD-11 (International Classification of Diseases, Eleventh Revision) Mortality and Morbidity Statistics code (958/6527, 14.7% with an exact relationship) and 94.8% (6191/6527) are mapped to Systematized Nomenclature of Medicine Clinical Terms (all with an exact relationship). Genetic disorders represent 72.2% (4715/6527) of all RDs, and 63.4% (4141/6527) are mapped to at least 1 phenotypic Online Mendelian Inheritance in Man number. The Orphanet Nomenclature and Classification of RDs is the only RDs-specific interoperable medical terminology meeting the needs of health care, research, and public health systems. By addressing the underrepresentation of RDs in medical terminologies, it enables accurate RDs identification, coding, and monitoring, supporting cross-border data interoperability, and contributing to improved knowledge, policymaking, and ultimately better care for people living with an RD.
- Open Access
- 11 June 2026
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 21 (1)
The estimated burden of rare diseases in South Africa using Orphanet: an epidemiological analysis
Background: Rare diseases (RDs) collectively affect a significant proportion of the population, yet their burden in South Africa (SA) remains poorly defined due to limited diagnostic capacity and infrastructure, inadequate epidemiological data and poor surveillance systems. Objective: To estimate the point prevalence of RDs in SA by integrating Orphanet-derived point prevalence data with national population statistics, identify disease characteristics and affected sub-groups, and assess the proportion of patients requiring high-cost treatments. Methods: A cross-sectional epidemiologic study was conducted using Orphanet’s validated methodology and four curated datasets (epidemiology, natural history, functional consequences, and medical domains). Inclusion criteria excluded cancers, infections, poisonings, and conditions without point prevalence data. RDs were classified by direct (population-based) or indirect (case/family report) point prevalence rates integrated with 2024 South African population estimates ( n = 63015904). Additional analyses were performed for age of onset, inheritance patterns, medical domains, associated disability, and access to high-cost treatment access in SA. Results: A total of 3728 RD were included in the study, relating to 58% of unique Orphanet disorder entities. The estimated mean point prevalence of these RDs in SA was 4.8% (range: 3.7%–5.9%), corresponding to 3030204 (range: 2321906–3738503) affected individuals. Only 11% of RDs accounted for 98% of this patient burden. Most conditions had childhood onset (77%) and were inherited in an autosomal recessive (42%) or autosomal dominant (27%) pattern. Approximately 1.33 million (44%) patients in SA are estimated to experience moderate to severe functional disabilities related to the 3728 RD in the study. High-cost treatment was applicable to < 5% of patients for included RD, yet only 25 of 59 globally approved orphan drugs are currently available in SA. Conclusion: This study provides the first national-level, evidence-based estimate of RD prevalence in SA using global Orphanet data. The findings confirm a substantial, mostly paediatric burden, with significant disability and limited treatment access. Results support investment in newborn screening, integrated community genetic services, early diagnosis, and equitable care models. These estimates offer a critical foundation for evidence-based national RD policy development and service planning, and a replicable approach for other low- and middle-income countries.
- 11 June 2026
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 21 (1)
Open AccessThe estimated burden of rare diseases in South Africa using Orphanet: an epidemiological analysis
Background: Rare diseases (RDs) collectively affect a significant proportion of the population, yet their burden in South Africa (SA) remains poorly defined due to limited diagnostic capacity and infrastructure, inadequate epidemiological data and poor surveillance systems. Objective: To estimate the point prevalence of RDs in SA by integrating Orphanet-derived point prevalence data with national population statistics, identify disease characteristics and affected sub-groups, and assess the proportion of patients requiring high-cost treatments. Methods: A cross-sectional epidemiologic study was conducted using Orphanet’s validated methodology and four curated datasets (epidemiology, natural history, functional consequences, and medical domains). Inclusion criteria excluded cancers, infections, poisonings, and conditions without point prevalence data. RDs were classified by direct (population-based) or indirect (case/family report) point prevalence rates integrated with 2024 South African population estimates ( n = 63015904). Additional analyses were performed for age of onset, inheritance patterns, medical domains, associated disability, and access to high-cost treatment access in SA. Results: A total of 3728 RD were included in the study, relating to 58% of unique Orphanet disorder entities. The estimated mean point prevalence of these RDs in SA was 4.8% (range: 3.7%–5.9%), corresponding to 3030204 (range: 2321906–3738503) affected individuals. Only 11% of RDs accounted for 98% of this patient burden. Most conditions had childhood onset (77%) and were inherited in an autosomal recessive (42%) or autosomal dominant (27%) pattern. Approximately 1.33 million (44%) patients in SA are estimated to experience moderate to severe functional disabilities related to the 3728 RD in the study. High-cost treatment was applicable to < 5% of patients for included RD, yet only 25 of 59 globally approved orphan drugs are currently available in SA. Conclusion: This study provides the first national-level, evidence-based estimate of RD prevalence in SA using global Orphanet data. The findings confirm a substantial, mostly paediatric burden, with significant disability and limited treatment access. Results support investment in newborn screening, integrated community genetic services, early diagnosis, and equitable care models. These estimates offer a critical foundation for evidence-based national RD policy development and service planning, and a replicable approach for other low- and middle-income countries.
- Open Access
- 22 September 2025
- Published by JMIR Publications Inc. in JMIR Preprints
The Orphanet Nomenclature and Classification of Rare Diseases for Improved Patient Recognition and Data Interoperability: Qualitative and Quantitative Analysis (Preprint)
BACKGROUND Although individually uncommon, rare diseases (RDs) collectively affect an estimated 329-624 million people worldwide. There are over 6500 known RDs, 85% of which affect fewer than 1 person per million. Consequently, the critical amount of data necessary to improve knowledge, care, and treatment can only be achieved through cumulative data collection across countries. However, RDs remain underrepresented in medical terminologies and classification systems, hindering data sharing, interoperability, and public health monitoring. OBJECTIVE This paper presents the Orphanet Nomenclature and Classification of RDs detailing its content, production and update methodology, and mappings to other semantic resources. It also provides an up-to-date count of RDs based on the consensus operational definition describing their distribution by medical domain. METHODS The Orphanet Nomenclature of RDs is a multilingual standardized system composed of clinical entities, each defined by a unique and time-stable ORPHAcode, a preferred term, synonyms, a classification level, and a textual definition. This nomenclature is structured into 3 classification levels organized within a multihierarchical and multiparental classification system by medical domain. Its production, updates, and mappings to major biomedical resources rely on standardized and published procedures, continuous literature review, manual curation, and expert validation, reflecting advancements in RDs knowledge and clinical practice. Presented data metrics were computed using the Orphanet July 2025 release to quantitatively characterize the content, structure, classification, and semantic alignments of the Orphanet Nomenclature and Classification system. RESULTS As of July 2025, the Orphanet Nomenclature of RDs includes a total of 9784 active clinical entities, including 6527 disorders (corresponding to the RDs definition), 1084 subtypes of disorders, and 2173 groups of disorders. Disorders are multiclassified into 29 classification hierarchies, each corresponding to a distinct medical domain, accurately representing the complex multisystemic nature of RDs. Extensive qualified mappings ensure semantic interoperability: 97.4% (6355/6527) of disorders are mapped to at least 1 ICD-10 (International Statistical Classification of Diseases, Tenth Revision) code (415/6527, 6.4% with an exact proximity relationship), 71.8% (4683/6527) are mapped to at least 1 ICD-11 (International Classification of Diseases, Eleventh Revision) Mortality and Morbidity Statistics code (958/6527, 14.7% with an exact relationship) and 94.8% (6191/6527) are mapped to Systematized Nomenclature of Medicine Clinical Terms (all with an exact relationship). Genetic disorders represent 72.2% (4715/6527) of all RDs, and 63.4% (4141/6527) are mapped to at least 1 phenotypic Online Mendelian Inheritance in Man number. CONCLUSIONS The Orphanet Nomenclature and Classification of RDs is the only RDs-specific interoperable medical terminology meeting the needs of health care, research, and public health systems. By addressing the underrepresentation of RDs in medical terminologies, it enables accurate RDs identification, coding, and monitoring, supporting cross-border data interoperability, and contributing to improved knowledge, policymaking, and ultimately better care for people living with an RD. CLINICALTRIAL
- 22 September 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessThe Orphanet Nomenclature and Classification of Rare Diseases for Improved Patient Recognition and Data Interoperability: Qualitative and Quantitative Analysis (Preprint)
BACKGROUND Although individually uncommon, rare diseases (RDs) collectively affect an estimated 329-624 million people worldwide. There are over 6500 known RDs, 85% of which affect fewer than 1 person per million. Consequently, the critical amount of data necessary to improve knowledge, care, and treatment can only be achieved through cumulative data collection across countries. However, RDs remain underrepresented in medical terminologies and classification systems, hindering data sharing, interoperability, and public health monitoring. OBJECTIVE This paper presents the Orphanet Nomenclature and Classification of RDs detailing its content, production and update methodology, and mappings to other semantic resources. It also provides an up-to-date count of RDs based on the consensus operational definition describing their distribution by medical domain. METHODS The Orphanet Nomenclature of RDs is a multilingual standardized system composed of clinical entities, each defined by a unique and time-stable ORPHAcode, a preferred term, synonyms, a classification level, and a textual definition. This nomenclature is structured into 3 classification levels organized within a multihierarchical and multiparental classification system by medical domain. Its production, updates, and mappings to major biomedical resources rely on standardized and published procedures, continuous literature review, manual curation, and expert validation, reflecting advancements in RDs knowledge and clinical practice. Presented data metrics were computed using the Orphanet July 2025 release to quantitatively characterize the content, structure, classification, and semantic alignments of the Orphanet Nomenclature and Classification system. RESULTS As of July 2025, the Orphanet Nomenclature of RDs includes a total of 9784 active clinical entities, including 6527 disorders (corresponding to the RDs definition), 1084 subtypes of disorders, and 2173 groups of disorders. Disorders are multiclassified into 29 classification hierarchies, each corresponding to a distinct medical domain, accurately representing the complex multisystemic nature of RDs. Extensive qualified mappings ensure semantic interoperability: 97.4% (6355/6527) of disorders are mapped to at least 1 ICD-10 (International Statistical Classification of Diseases, Tenth Revision) code (415/6527, 6.4% with an exact proximity relationship), 71.8% (4683/6527) are mapped to at least 1 ICD-11 (International Classification of Diseases, Eleventh Revision) Mortality and Morbidity Statistics code (958/6527, 14.7% with an exact relationship) and 94.8% (6191/6527) are mapped to Systematized Nomenclature of Medicine Clinical Terms (all with an exact relationship). Genetic disorders represent 72.2% (4715/6527) of all RDs, and 63.4% (4141/6527) are mapped to at least 1 phenotypic Online Mendelian Inheritance in Man number. CONCLUSIONS The Orphanet Nomenclature and Classification of RDs is the only RDs-specific interoperable medical terminology meeting the needs of health care, research, and public health systems. By addressing the underrepresentation of RDs in medical terminologies, it enables accurate RDs identification, coding, and monitoring, supporting cross-border data interoperability, and contributing to improved knowledge, policymaking, and ultimately better care for people living with an RD. CLINICALTRIAL
- Open Access
The Orphanet Nomenclature and Classification of rare diseases: a standard terminology for improved patient recognition and data interoperability
Background: Although individually uncommon, rare diseases (RD) collectively affect an estimated 329-624 million people worldwide There are over 6,500 known RD, 85% of which affect fewer than 1 person per million. As a result, the critical amount of data necessary to improve knowledge, care, and treatment can only be achieved through cumulative data collection across different countries in a standardized manner. However, RD are under-represented in medical terminologies and classification systems, hindering data sharing, interoperability, and public health monitoring. Objective: The aim of this paper is to present the Orphanet Nomenclature and Classification of RD. We detail its content as well as its production and update methodology, and an overview of its mappings to other semantic resources. In addition, this work provides a clear and up-to-date count of RD based on the consensus operational definition of RD, and it details the distribution of RD by medical domain. Methods: The Orphanet Nomenclature of RD is a multilingual standardized system composed of clinical entities, each defined by a unique and time-stable ORPHAcode, a preferred term, synonyms, a classification level, and a textual definition. This nomenclature is structured into three classification levels organized within a multi-hierarchical and multi-parental classification system by medical domain. Its production, updates, and mappings to major biomedical resources rely on standardized and published procedures, continuous literature review, manual curation and expert validation, reflecting advancements in RD knowledge and clinical practice. Presented data metrics were computed using the Orphanet July 2025 release to quantitatively characterize the content, structure, classification, and semantic alignments of the Orphanet Nomenclature and Classification system. Results: As of July 2025, the Orphanet Nomenclature of RD includes a total of 9,784 active clinical entities, including 6,527 disorders (corresponding to the RD definition), 1,084 subtypes of disorders, and 2,173 groups of disorders. Disorders are multiclassified into 29 classification hierarchies, each corresponding to a distinct medical domain, accurately representing the complex multisystemic nature of RD. Extensive qualified mappings ensure semantic interoperability: 97.4% of disorders are mapped to at least one ICD-10 code (6.4% with an exact proximity relationship), 71.8% are mapped to at least one ICD-11 MMS code (14.7% with an exact relationship) and 94.8% are mapped to SNOMED CT (all with an exact relationship). Genetic disorders represent 72.2% of all RD, and 63.4% are mapped to at least one phenotypic OMIM number. Conclusions: The Orphanet Nomenclature and Classification of RD is the only RD-specific interoperable medical terminology meeting the needs of healthcare, research, and public health systems. By addressing the underrepresentation of RD in medical terminologies, it enables accurate RD identification, coding, and monitoring, supporting cross-border data interoperability, and contributing to improved knowledge, policy-making, and ultimately better care for people living with a RD.
Open AccessThe Orphanet Nomenclature and Classification of rare diseases: a standard terminology for improved patient recognition and data interoperability
Background: Although individually uncommon, rare diseases (RD) collectively affect an estimated 329-624 million people worldwide There are over 6,500 known RD, 85% of which affect fewer than 1 person per million. As a result, the critical amount of data necessary to improve knowledge, care, and treatment can only be achieved through cumulative data collection across different countries in a standardized manner. However, RD are under-represented in medical terminologies and classification systems, hindering data sharing, interoperability, and public health monitoring. Objective: The aim of this paper is to present the Orphanet Nomenclature and Classification of RD. We detail its content as well as its production and update methodology, and an overview of its mappings to other semantic resources. In addition, this work provides a clear and up-to-date count of RD based on the consensus operational definition of RD, and it details the distribution of RD by medical domain. Methods: The Orphanet Nomenclature of RD is a multilingual standardized system composed of clinical entities, each defined by a unique and time-stable ORPHAcode, a preferred term, synonyms, a classification level, and a textual definition. This nomenclature is structured into three classification levels organized within a multi-hierarchical and multi-parental classification system by medical domain. Its production, updates, and mappings to major biomedical resources rely on standardized and published procedures, continuous literature review, manual curation and expert validation, reflecting advancements in RD knowledge and clinical practice. Presented data metrics were computed using the Orphanet July 2025 release to quantitatively characterize the content, structure, classification, and semantic alignments of the Orphanet Nomenclature and Classification system. Results: As of July 2025, the Orphanet Nomenclature of RD includes a total of 9,784 active clinical entities, including 6,527 disorders (corresponding to the RD definition), 1,084 subtypes of disorders, and 2,173 groups of disorders. Disorders are multiclassified into 29 classification hierarchies, each corresponding to a distinct medical domain, accurately representing the complex multisystemic nature of RD. Extensive qualified mappings ensure semantic interoperability: 97.4% of disorders are mapped to at least one ICD-10 code (6.4% with an exact proximity relationship), 71.8% are mapped to at least one ICD-11 MMS code (14.7% with an exact relationship) and 94.8% are mapped to SNOMED CT (all with an exact relationship). Genetic disorders represent 72.2% of all RD, and 63.4% are mapped to at least one phenotypic OMIM number. Conclusions: The Orphanet Nomenclature and Classification of RD is the only RD-specific interoperable medical terminology meeting the needs of healthcare, research, and public health systems. By addressing the underrepresentation of RD in medical terminologies, it enables accurate RD identification, coding, and monitoring, supporting cross-border data interoperability, and contributing to improved knowledge, policy-making, and ultimately better care for people living with a RD.
- Open Access
- 8 July 2025
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 20 (1) , 1-15
Revised orphanet nomenclature and classification for spina bifida and other spinal dysraphisms (SBoD)
Background: The Spina Bifida and other Dysraphisms working group (SBoD WG) is an interdisciplinary group, comprising experts on spinal dysraphism from 11 European countries. In 2022, the SBoD WG was tasked by 2 European Rare Disease Networks (ERN ITHACA and ERN eUROGEN) to revise the Orphanet classification of spinal dysraphism. Over the past two decades numerous subcategories of spinal dysraphism have been described in the medical literature resulting in a proliferation of terms, numerous synonyms and variously applied definitions. In the light of this, a revision of all terms and definitions was conducted by a Delphi approach in 3 steps by neurosurgeons (fetal/paediatric/adult), urologists (paediatric/adult), rehabilitation medicine specialists, fetal medicine and perinatal imaging specialists, geneticists, pathologists, nephrologists and patient representatives, all members of the International Federation for Spina Bifida and Hydrocephalus (IFSBH). Results: In the first instance, 39 experts reviewed and refined the terminology that could be used to describe the anatomical characteristics of all forms of SBoD. At the second stage, 24 experts established terms and unambiguous definitions for 16 skin findings, 7 bone findings and 33 spinal cord findings that were considered essential features capable of describing all forms of spinal dysraphism. In the third stage, 29 experts validated 24 spinal dysraphic anomalies using these pre-agreed findings. All terms and definitions were validated by vote with a threshold of 80% approval (abstention was permitted). No terms with disagreement were retained in the subsequent classification. The revised SBoD classification was transferred to the Orphanet nomenclature (ORPHA:823). 16 existing ORPHAcodes were deemed obsolete, 10 ORPHAcodes were updated (terms and/or textual definitions) and 25 new ORPHAcodes were created. The SBoD working group also developed a ‘decision tree’ for new users, to assist them in the practical aspects of applying the revised classification and designating appropriate ORPHAcodes. Conclusions: An update of the Orphanet Classification of spinal dysraphism was conducted by a European interdisciplinary group of experts encompassing all aspects of healthcare for patients with these disorders. This new classification, based on essential skin, bone and spinal cord findings offers a more logical and reproducible means to categorise SBoD. It is hoped that this will permit more precise disease delineation, consistent diagnostic accuracy and better prognostication.
- 8 July 2025
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 20 (1) , 1-15
Open AccessRevised orphanet nomenclature and classification for spina bifida and other spinal dysraphisms (SBoD)
Background: The Spina Bifida and other Dysraphisms working group (SBoD WG) is an interdisciplinary group, comprising experts on spinal dysraphism from 11 European countries. In 2022, the SBoD WG was tasked by 2 European Rare Disease Networks (ERN ITHACA and ERN eUROGEN) to revise the Orphanet classification of spinal dysraphism. Over the past two decades numerous subcategories of spinal dysraphism have been described in the medical literature resulting in a proliferation of terms, numerous synonyms and variously applied definitions. In the light of this, a revision of all terms and definitions was conducted by a Delphi approach in 3 steps by neurosurgeons (fetal/paediatric/adult), urologists (paediatric/adult), rehabilitation medicine specialists, fetal medicine and perinatal imaging specialists, geneticists, pathologists, nephrologists and patient representatives, all members of the International Federation for Spina Bifida and Hydrocephalus (IFSBH). Results: In the first instance, 39 experts reviewed and refined the terminology that could be used to describe the anatomical characteristics of all forms of SBoD. At the second stage, 24 experts established terms and unambiguous definitions for 16 skin findings, 7 bone findings and 33 spinal cord findings that were considered essential features capable of describing all forms of spinal dysraphism. In the third stage, 29 experts validated 24 spinal dysraphic anomalies using these pre-agreed findings. All terms and definitions were validated by vote with a threshold of 80% approval (abstention was permitted). No terms with disagreement were retained in the subsequent classification. The revised SBoD classification was transferred to the Orphanet nomenclature (ORPHA:823). 16 existing ORPHAcodes were deemed obsolete, 10 ORPHAcodes were updated (terms and/or textual definitions) and 25 new ORPHAcodes were created. The SBoD working group also developed a ‘decision tree’ for new users, to assist them in the practical aspects of applying the revised classification and designating appropriate ORPHAcodes. Conclusions: An update of the Orphanet Classification of spinal dysraphism was conducted by a European interdisciplinary group of experts encompassing all aspects of healthcare for patients with these disorders. This new classification, based on essential skin, bone and spinal cord findings offers a more logical and reproducible means to categorise SBoD. It is hoped that this will permit more precise disease delineation, consistent diagnostic accuracy and better prognostication.
- Top Cited PapersOpen Access
- 11 November 2023
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 52 (D1) , D1333-D1346
The Human Phenotype Ontology in 2024: phenotypes around the world
The Human Phenotype Ontology (HPO) is a widely used resource that comprehensively organizes and defines the phenotypic features of human disease, enabling computational inference and supporting genomic and phenotypic analyses through semantic similarity and machine learning algorithms. The HPO has widespread applications in clinical diagnostics and translational research, including genomic diagnostics, gene-disease discovery, and cohort analytics. In recent years, groups around the world have developed translations of the HPO from English to other languages, and the HPO browser has been internationalized, allowing users to view HPO term labels and in many cases synonyms and definitions in ten languages in addition to English. Since our last report, a total of 2239 new HPO terms and 49235 new HPO annotations were developed, many in collaboration with external groups in the fields of psychiatry, arthrogryposis, immunology and cardiology. The Medical Action Ontology (MAxO) is a new effort to model treatments and other measures taken for clinical management. Finally, the HPO consortium is contributing to efforts to integrate the HPO and the GA4GH Phenopacket Schema into electronic health records (EHRs) with the goal of more standardized and computable integration of rare disease data in EHRs.
- 11 November 2023
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 52 (D1) , D1333-D1346
Top Cited PapersOpen AccessThe Human Phenotype Ontology in 2024: phenotypes around the world
The Human Phenotype Ontology (HPO) is a widely used resource that comprehensively organizes and defines the phenotypic features of human disease, enabling computational inference and supporting genomic and phenotypic analyses through semantic similarity and machine learning algorithms. The HPO has widespread applications in clinical diagnostics and translational research, including genomic diagnostics, gene-disease discovery, and cohort analytics. In recent years, groups around the world have developed translations of the HPO from English to other languages, and the HPO browser has been internationalized, allowing users to view HPO term labels and in many cases synonyms and definitions in ten languages in addition to English. Since our last report, a total of 2239 new HPO terms and 49235 new HPO annotations were developed, many in collaboration with external groups in the fields of psychiatry, arthrogryposis, immunology and cardiology. The Medical Action Ontology (MAxO) is a new effort to model treatments and other measures taken for clinical management. Finally, the HPO consortium is contributing to efforts to integrate the HPO and the GA4GH Phenopacket Schema into electronic health records (EHRs) with the goal of more standardized and computable integration of rare disease data in EHRs.
- Open Access
- 6 November 2023
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 32 (2) , 182-189
Phenotypic similarity-based approach for variant prioritization for unsolved rare disease: a preliminary methodological report
Rare diseases (RD) have a prevalence of not more than 1/2000 persons in the European population, and are characterised by the difficulty experienced in obtaining a correct and timely diagnosis. According to Orphanet, 72.5% of RD have a genetic origin although 35% of them do not yet have an identified causative gene. A significant proportion of patients suspected to have a genetic RD receive an inconclusive exome/genome sequencing. Working towards the International Rare Diseases Research Consortium (IRDiRC)’s goal for 2027 to ensure that all people living with a RD receive a diagnosis within one year of coming to medical attention, the Solve-RD project aims to identify the molecular causes underlying undiagnosed RD. As part of this strategy, we developed a phenotypic similarity-based variant prioritization methodology comparing submitted cases with other submitted cases and with known RD in Orphanet. Three complementary approaches based on phenotypic similarity calculations using the Human Phenotype Ontology (HPO), the Orphanet Rare Diseases Ontology (ORDO) and the HPO-ORDO Ontological Module (HOOM) were developed; genomic data reanalysis was performed by the RD-Connect Genome-Phenome Analysis Platform (GPAP). The methodology was tested in 4 exemplary cases discussed with experts from European Reference Networks. Variants of interest (pathogenic or likely pathogenic) were detected in 8.8% of the 725 cases clustered by similarity calculations. Diagnostic hypotheses were validated in 42.1% of them and needed further exploration in another 10.9%. Based on the promising results, we are devising an automated standardized phenotypic-based re-analysis pipeline to be applied to the entire unsolved cases cohort.
- 6 November 2023
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 32 (2) , 182-189
Open AccessPhenotypic similarity-based approach for variant prioritization for unsolved rare disease: a preliminary methodological report
Rare diseases (RD) have a prevalence of not more than 1/2000 persons in the European population, and are characterised by the difficulty experienced in obtaining a correct and timely diagnosis. According to Orphanet, 72.5% of RD have a genetic origin although 35% of them do not yet have an identified causative gene. A significant proportion of patients suspected to have a genetic RD receive an inconclusive exome/genome sequencing. Working towards the International Rare Diseases Research Consortium (IRDiRC)’s goal for 2027 to ensure that all people living with a RD receive a diagnosis within one year of coming to medical attention, the Solve-RD project aims to identify the molecular causes underlying undiagnosed RD. As part of this strategy, we developed a phenotypic similarity-based variant prioritization methodology comparing submitted cases with other submitted cases and with known RD in Orphanet. Three complementary approaches based on phenotypic similarity calculations using the Human Phenotype Ontology (HPO), the Orphanet Rare Diseases Ontology (ORDO) and the HPO-ORDO Ontological Module (HOOM) were developed; genomic data reanalysis was performed by the RD-Connect Genome-Phenome Analysis Platform (GPAP). The methodology was tested in 4 exemplary cases discussed with experts from European Reference Networks. Variants of interest (pathogenic or likely pathogenic) were detected in 8.8% of the 725 cases clustered by similarity calculations. Diagnostic hypotheses were validated in 42.1% of them and needed further exploration in another 10.9%. Based on the promising results, we are devising an automated standardized phenotypic-based re-analysis pipeline to be applied to the entire unsolved cases cohort.
- Open Access
- 4 September 2023
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 18 (1) , 1-10
ORPHAcodes use for the coding of rare diseases: comparison of the accuracy and cross country comparability
Background: Estimates of rare disease (RD) population impact in terms of number of affected patients and accurate disease definition is hampered by their under-representation in current coding systems. This study tested the use of a specific RD codification system (ORPHAcodes) in five European countries/regions (Czech Republic, Malta, Romania, Spain, Veneto region-Italy) across different data sources over the period January 2019-September 2021. Results: Overall, 3133 ORPHAcodes were used to describe RD diagnoses, mainly corresponding to the disease/subtype of disease aggregation level of the Orphanet classification (82.2%). More than half of the ORPHAcodes (53.6%) described diseases having a very low prevalence (< 1 case per million), and most commonly captured rare developmental defects during embryogenesis (31.3%) and rare neurological diseases (17.6%). ORPHAcodes described disease entities more precisely than corresponding ICD-10 codes in 83.4% of cases. Conclusions: ORPHAcodes were found to be a versatile resource for the coding of RD, able to assure easiness of use and inter-country comparability across population and hospital databases. Future research on the impact of ORPHAcoding as to the impact of numbers of RD patients with improved coding in health information systems is needed to inform on the real magnitude of this public health issue.
- 4 September 2023
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 18 (1) , 1-10
Open AccessORPHAcodes use for the coding of rare diseases: comparison of the accuracy and cross country comparability
Background: Estimates of rare disease (RD) population impact in terms of number of affected patients and accurate disease definition is hampered by their under-representation in current coding systems. This study tested the use of a specific RD codification system (ORPHAcodes) in five European countries/regions (Czech Republic, Malta, Romania, Spain, Veneto region-Italy) across different data sources over the period January 2019-September 2021. Results: Overall, 3133 ORPHAcodes were used to describe RD diagnoses, mainly corresponding to the disease/subtype of disease aggregation level of the Orphanet classification (82.2%). More than half of the ORPHAcodes (53.6%) described diseases having a very low prevalence (< 1 case per million), and most commonly captured rare developmental defects during embryogenesis (31.3%) and rare neurological diseases (17.6%). ORPHAcodes described disease entities more precisely than corresponding ICD-10 codes in 83.4% of cases. Conclusions: ORPHAcodes were found to be a versatile resource for the coding of RD, able to assure easiness of use and inter-country comparability across population and hospital databases. Future research on the impact of ORPHAcoding as to the impact of numbers of RD patients with improved coding in health information systems is needed to inform on the real magnitude of this public health issue.